Prompt, Aggressive BP Lowering in High-Risk Patients

被引:12
作者
Jamerson, Kenneth A. [1 ]
Basile, Jan [2 ,3 ]
机构
[1] Univ Michigan Hlth Care Syst, Ann Arbor, MI USA
[2] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC USA
[3] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC USA
关键词
D O I
10.1111/j.1524-6175.2007.08145.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Various populations with hypertension have been singled out by current treatment guidelines as requiring more specific treatment. These include patients with stage 2 hypertension, black patients, and patients with coexistent diabetes mellitus and coronary heart disease. Hypertension in these groups is often associated with higher risk of cardiovascular morbidity and mortality. This article reviews current knowledge regarding hypertension in high-risk patient populations, with a particular focus on the importance of prompt, aggressive treatment to lower blood pressure and prevent cardiovascular disease progression. Such treatment includes the earl), use of multiple-drug therapy with agents that have complementary blood pressure-lowering mechanisms and provide protection from target, organ damage. While 2- or 3-drug antihypertensive therapy in these high-risk groups has typically included a diuretic, other combinations of agents may be indicated. Evidence suggests that therapy with a calcium channel blocker and an inhibitor of the renin-angiotensin system is one effective strategy for lowering blood pressure and improving outcomes in these populations. (J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):40-48) (c) 2008 Le Jacq
引用
收藏
页码:40 / 48
页数:9
相关论文
共 69 条
[1]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[2]   Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population [J].
Aksnes, Tonje A. ;
Kjeldsen, Sverre E. ;
Rostrup, Morten ;
Omvik, Per ;
Hua, Tsushung A. ;
Julius, Stevo .
HYPERTENSION, 2007, 50 (03) :467-473
[3]   Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up [J].
Almgren, Torbjorn ;
Wilhelmsen, Lars ;
Samuelsson, Ola ;
Himmelmann, Anders ;
Rosengren, Annika ;
Andersson, Ove K. .
JOURNAL OF HYPERTENSION, 2007, 25 (06) :1311-1317
[4]  
*AM HEART ASS, 2007, HEART DIS STROK STAT
[5]   Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) [J].
Andraws, Richard ;
Brown, David L. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (07) :1006-1012
[6]  
[Anonymous], 2000, BMJ-BRIT MED J, DOI DOI 10.1161/01.HYP.0000107251.49515.c2
[7]  
[Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
[8]  
Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65
[9]  
BAKRIS G, 2007, J HUM HYPERTENS 0830
[10]  
Bakris George L, 2003, J Clin Hypertens (Greenwich), V5, P202, DOI 10.1111/j.1524-6175.2002.2041.x